Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Stuart A. Scott,Katrin Sangkuhl,Charles M. Stein,Jean-Sébastien Hulot,Jean-Sébastien Hulot,Jessica L. Mega,Dan M. Roden,Teri E. Klein,Marc S. Sabatine,Julie A. Johnson,Julie A. Johnson,Alan R. Shuldiner,Alan R. Shuldiner +12 more
Reads0
Chats0
TLDR
In this article, an expanded literature review showed that CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI).Abstract:
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype–directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).read more
Citations
More filters
Journal ArticleDOI
Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public health
TL;DR: In this paper, the authors provide an extensive updated analysis of population pharmacogenomics in ten pharmacokinetic genes (CYP2D6, CYP2C19, DPYD, TPMT, NUDT15 and SLC22A1), drug targets (CFTR) and genes involved in drug hypersensitivity (HLA-A, HLA-B) or drug-induced acute hemolytic anemia (G6PD).
Journal ArticleDOI
Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort
TL;DR: It is concluded that pharmacokinetic interaction between PPIs and antiplatelet therapy is not associated with adverse CV events and a comprehensive, multicenter, open-label trial including all PPI subclasses and patient and disease-based factors is warranted for a fair evaluation.
Journal ArticleDOI
The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
K. B. Mirzaev,Eric Rytkin,Kristina A Ryzhikova,Elena A. Grishina,Zhannet A Sozaeva,Denis S Fedorinov,Olga D. Konova,Michael Iu Giliarov,Galina A Belyakova,Denis Andreev,Dmitriy A. Sychev +10 more
TL;DR: The reactivity of the on-clopidogrel platelet in the early phase of ACS is influenced primarily by the CYP2C19 polymorphisms, and the findings of the present study could supply additional evidence regarding the clinical appropriateness of the CYC19 genetic testing for designing suitable antiplatelet therapy in theEarly phase ofACS.
Journal ArticleDOI
Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia).
Denis S Fedorinov,K. B. Mirzaev,D. V. Ivashchenko,Ilyas I. Temirbulatov,Dmitriy A. Sychev,N. R. Maksimova,Jana Valer'evna Chertovskih,Nyurguiana V. Popova,Ksenia S. Tayurskaya,Zoya A. Rudykh +9 more
TL;DR: The results of the present study may be helpful for developing guidelines for CYPC19 genotype-directed antiplatelet therapy for Yakut and Russian patients.
Journal ArticleDOI
Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Ji Hyun Lee,Sung Gyun Ahn,Sung Gyun Ahn,Jun Won Lee,Young Jin Youn,Min Soo Ahn,Jang Young Kim,Byung Su Yoo,Seung Hwan Lee,Junghan Yoon,Juwon Kim,Eunhee Choi,Sang Yong Yoo,Olivia Y. Hung,Habib Samady +14 more
TL;DR: Individualized antiplatelet regimens based on CYP2C19 genotyping may improve likelihood of achieving a TW of OPR compared to fixed dose of prasugrel 10 mg during maintenance periods of AMI in East Asians.
References
More filters
Journal ArticleDOI
Meta-Analysis: A Constantly Evolving Research Integration Tool
TL;DR: The four articles in this special section onMeta-analysis illustrate some of the complexities entailed in meta-analysis methods and contributes both to advancing this methodology and to the increasing complexities that can befuddle researchers.
Journal ArticleDOI
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Stephen D. Wiviott,Eugene Braunwald,Carolyn H. McCabe,Gilles Montalescot,Witold Rużyłło,Shmuel Gottlieb,Franz Joseph Neumann,Diego Ardissino,Stefano De Servi,Sabina A. Murphy,Jeffrey S. Riesmeyer,Govinda Weerakkody,C. Michael Gibson,Elliott M. Antman +13 more
TL;DR: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding.
Journal ArticleDOI
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin,Richard C. Becker,Andrzej Budaj,Christopher P. Cannon,Håkan Emanuelsson,Claes Held,Jay Horrow,Steen Husted,Stefan James,Hugo A. Katus,Kenneth W. Mahaffey,Benjamin M. Scirica,Allan M. Skene,Philippe Gabriel Steg,Robert F. Storey,Robert A. Harrington +15 more
TL;DR: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.
A Systematic Review and Meta-analysis
TL;DR: A systematic review of studies published from January 1, 1950, through November 31, 2008 using PubMed, EMBASE, Web of Knowledge, CINAHL, and all Evidence-Based Medicine Reviews found that randomized clinical trials and prospective studies of RRTs that reported data on changes in the primary outcome of hospital mortality or the secondary outcome of cardiopulmonary arrest cases were included.
Journal ArticleDOI
Genetic Structure of Human Populations
Noah A. Rosenberg,Jonathan K. Pritchard,James L. Weber,Howard M. Cann,Kenneth K. Kidd,Lev A. Zhivotovsky,Marcus W. Feldman +6 more
TL;DR: General agreement of genetic and predefined populations suggests that self-reported ancestry can facilitate assessments of epidemiological risks but does not obviate the need to use genetic information in genetic association studies.
Related Papers (5)
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Jessica L. Mega,Tabassome Simon,Jean-Philippe Collet,Jeffrey L. Anderson,Elliott M. Antman,Kevin P. Bliden,Christopher P. Cannon,Nicolas Danchin,Betti Giusti,Paul A. Gurbel,Benjamin D. Horne,Jean Sebastian Hulot,Adnan Kastrati,Gilles Montalescot,Franz-Josef Neumann,Lei Shen,Dirk Sibbing,P. Gabriel Steg,Dietmar Trenk,Stephen D. Wiviott,Marc S. Sabatine +20 more